Literature DB >> 23772278

PCSK9 - A New and Potent Approach to Lowering Cholesterol.

Thomas F Whayne1.   

Abstract

Entities:  

Year:  2013        PMID： 23772278      PMCID： PMC3679611          DOI： 10.5001/omj.2013.45

Source DB:  PubMed          Journal:  Oman Med J        ISSN： 1999-768X


× No keyword cloud information.
  27 in total

Review 1.  Molecular biology of PCSK9: its role in LDL metabolism.

Authors:  Jay D Horton; Jonathan C Cohen; Helen H Hobbs
Journal:  Trends Biochem Sci       Date:  2007-01-09       Impact factor: 13.807

Review 2.  Current status of CETP inhibitors in the treatment of hyperlipidemia: an update.

Authors:  Raktim Kumar Ghosh; Samhati Mondal Ghosh
Journal:  Curr Clin Pharmacol       Date:  2012-05

3.  The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results.

Authors:  D H Blankenhorn; R L Johnson; S A Nessim; S P Azen; M E Sanmarco; R H Selzer
Journal:  Control Clin Trials       Date:  1987-12

4.  Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.

Authors:  James M McKenney; Michael J Koren; Dean J Kereiakes; Corinne Hanotin; Anne-Catherine Ferrand; Evan A Stein
Journal:  J Am Coll Cardiol       Date:  2012-03-28       Impact factor: 24.094

5.  Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.

Authors:  Stephen D Wiviott; Christopher P Cannon; David A Morrow; Kausik K Ray; Marc A Pfeffer; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2005-10-18       Impact factor: 24.094

6.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

7.  Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias.

Authors:  H Buchwald; R L Varco; J R Boen; S E Williams; B J Hansen; C T Campos; G S Campbell; M B Pearce; A E Yellin; W A Edmiston; R D Smink; H S Sawin
Journal:  Arch Intern Med       Date:  1998-06-08

8.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

9.  A nonsense mutation in the LDL receptor gene leads to familial hypercholesterolemia in the Druze sect.

Authors:  D Landsberger; V Meiner; A Reshef; Y Levy; D R van der Westhuyzen; G A Coetzee; E Leitersdorf
Journal:  Am J Hum Genet       Date:  1992-02       Impact factor: 11.025

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.